Dengue Vaccine Qdenga Arrives in India by 2027

Takeda's Qdenga dengue vaccine is anticipated to be available in India during the first half of 2027. A distribution agreement has been established between Dr Reddy's Laboratories and Takeda Pharmaceutical Company. Under this agreement, Dr Reddy's will promote and distribute Qdenga throughout India's private market, catering to both pediatric and adult vaccination needs.

This partnership signifies a crucial step as Qdenga received marketing authorization from the CDSCO in July 2026, marking it as India's first approved dengue vaccine for individuals aged 4 to 60 years. While inclusion in the public immunization program is a future goal, the private market availability will offer an immediate pathway for access.

Qdenga, a live-attenuated tetravalent vaccine, targets all four dengue serotypes and is administered in two doses. Dengue poses a significant and growing public health threat in India, with cases rising substantially over the past two decades and multiple serotypes co-circulating, impacting a notable portion of patients concurrently.